Shares of Alvotech jumped 6.4% to ISK 662 on Monday after the company announced — before the Iceland session opened — that the FDA had approved a new manufacturing process for its flagship Humira copycat, SIMLANDI. The approval lets Alvotech introduce what it calls "Process 2.0" in its Reykjavik factory, more than doubling drug substance output per batch without changing the manufacturing scale. For a company still fighting to turn consistent profits, the news removes a critical bottleneck — but also raises questions about what comes next.
• Producing More With Less Directly Cuts Cost Per Dose. By more than doubling output per batch, Alvotech can now produce the same volume of its Humira biosimilar in fewer manufacturing runs, freeing capacity for other products. In biosimilar economics — where margins hinge on unit costs — that kind of efficiency gain flows almost straight to the bottom line. The company reported a gross margin of 54% in the first half of 2026 ; higher throughput per batch could meaningfully widen that figure in coming quarters.
• The Real Prize May Be Clearing the Path for New Products. Alvotech said it expects the FDA to be able to act on pending applications for biosimilars of Simponi, Eylea, Prolia/Xgeva, and Entyvio — all of which are tied to the same Reykjavik facility. Those four drugs represent tens of billions of dollars in branded sales globally. Entyvio alone now has about $7.5 billion in worldwide brand sales. Every factory hour freed by Process 2.0 is an hour available for these launches.
• Revenue Guidance Leaves Room — But Also Doubt. Management has guided for 2026 revenue of $650–$700 million and EBITDA of $180–$220 million , yet first-half adjusted revenue came in at just $211.9 million, down from $306.1 million a year earlier , partly due to production slowdowns during facility upgrades. Hitting full-year targets now depends heavily on a second-half surge backed by this newly approved process.
• Alvotech's Cash Runway Remains Tight. The company secured $240 million in new capital this summer — a $165 million equity raise plus a $75 million loan facility — to fund pipeline launches and operations.
It posted a razor-thin $1 million profit in Q1 2026. Investors betting on today's rally are wagering that doubling SIMLANDI output accelerates the company past its break-even tipping point before that cash runs out. The manufacturing win is real, but the margin for error remains slim.